Lars Lannfelt, through the holding company Demban AB, and Pär Gellerfors, through the holding company Ackelsta AB, have sold 2,400,000 class B shares in BioArctic AB (publ).
BioArctic is a Swedish research-intensive biopharmaceutical company aiming to develop new treatments that address the causes of neurodegenerative diseases. Neurodegenerative diseases are diseases that affect the brain, spinal cord or peripheral nerves and where there is a gradual degradation of the nerve tissue. We focus on disease-modifying treatments for Alzheimer’s disease, Parkinson’s disease and ALS.
DNB Carnegie Investment Bank, RBC Capital Markets and Van Lanschot Kempen acted as Joint Bookrunners. Baker McKenzie acted as legal adviser to the Joint Bookrunners with an international capital markets team consisting of Henric Roth, Joakim Falkner and Olof Larsson in Stockholm as well as Adam Farlow and Charles Farnsworth in London.